1-(tert-Butyl)-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

Catalog No. :
ACOSCB984
CAS No. :
1353003-02-7
Molecular Formula :
C14H25BN2O2
Molecular Weight :
264.18

IUPAC Name:1-(tert-butyl)-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

1-(tert-Butyl)-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(tert-Butyl)-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
IUPAC Name1-(tert-butyl)-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Molecular FormulaC14H25BN2O2
Molecular Weight264.18
SMILESCC1(C)C(C)(C)OB(C2=CN(C(C)(C)C)N=C2C)O1
InChI KeyPNQCLMLQVUUDBF-UHFFFAOYSA-N
Synonym1H-Pyrazole, 1-(1,1-dimethylethyl)-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1353003-02-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACOSCB984 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOSCB984 route product structure diagram
    ACOSCB9841353003-02-7
Inquiry

2. ACOSCB984 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACMHCN687 route compound structure diagram
    ACMHCN687936250-20-3 In Stock
  4. Then
  5. ACOSCB984 route product structure diagram
    ACOSCB9841353003-02-7
Inquiry

Comments (0)